GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
February 05, 2014 02:00 ET
|
GW Pharmaceuticals plc
-Recent Successful $101 Million Financing Accelerates Epidiolex® Development
in Childhood Epilepsy-
-Conference Call Today at 8:00 a.m. ET, 1:00 p.m. GMT-
LONDON, Feb. 5, 2014 (GLOBE...
GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014
January 29, 2014 02:00 ET
|
GW Pharmaceuticals plc
LONDON, Jan. 29, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing...
GW Pharmaceuticals plc Announces the Closing of Its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs
January 14, 2014 11:17 ET
|
GW Pharmaceuticals plc
LONDON, Jan. 14, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing...
Ipsen and GW Pharmaceuticals plc Enter Into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America
January 14, 2014 02:00 ET
|
GW Pharmaceuticals plc
The intended indication for Sativex® is the treatment of spasticity due to multiple sclerosis
Sativex® a companion drug to Dysport® in neurology
LONDON and PARIS, Jan. 14,...